サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1671994

尿路上皮がん診断の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Urothelial Carcinoma Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 191 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
尿路上皮がん診断の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月24日
発行: Persistence Market Research
ページ情報: 英文 191 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の尿路上皮がん診断の市場規模は、2025年に18億4,480万米ドルになるとみられ、2025年～2032年の予測期間に10.9%のCAGRで拡大し、2032年には38億3,130万米ドルに達すると予測されています。

一般に膀胱がんと呼ばれる尿路上皮がんは、効果的な治療と患者の転帰のために早期かつ正確な診断が必要とされる悪性腫瘍です。尿路上皮がん診断市場には、尿細胞診、バイオマーカー検査、蛍光in situハイブリダイゼーション（FISH）、膀胱鏡検査、画像技術など、さまざまな診断法が含まれます。これらの診断法は、疾患の検出、病期分類、再発のモニタリングにおいて重要な役割を果たしています。市場成長の原動力は、診断技術の進歩、膀胱がん罹患率の増加、非侵襲的診断アプローチの採用拡大、患者の利便性向上と早期発見率です。

世界の尿路上皮がん診断市場は、特に高齢化社会と喫煙や工業化学物質への曝露などの高リスク因子を持つ人々の間で膀胱がん有病率が上昇していることなど、いくつかの主要な要因によって推進されています。また、尿ベースのバイオマーカー検査など、非侵襲的で低侵襲な診断方法への嗜好の高まりも市場拡大に寄与しています。さらに、分子診断や人工知能を活用した画像診断ソリューションの技術進歩により、診断の精度と効率が向上しています。リキッドバイオプシーと次世代シークエンシング（NGS）の統合が進んでいることも、尿路上皮がん患者に正確で個別化された診断洞察を提供することで市場の成長をさらに後押ししています。

尿路上皮がん診断市場は、画像診断における人工知能と機械学習の採用の増加、精密医療アプローチの拡大、早期がん検出プログラムへの注目の高まりによって、大きな成長機会がもたらされます。デジタル病理学およびAI支援診断プラットフォームの進歩は、診断効率を高め、偽陽性または偽陰性の可能性を低減し、患者の転帰を改善します。さらに、尿路上皮がんに対する費用対効果の高い迅速なポイントオブケア診断ソリューションの開発は、十分なサービスを受けていない地域での市場開拓を促進する可能性があります。バイオマーカーの発見と検証を進めるための診断企業と研究機関の提携も、この発展途上の市場において有利な成長の見通しをもたらします。

当レポートでは、世界の尿路上皮がん診断市場について調査し、製品別、検査別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

第4章 世界の尿路上皮がん診断市場の見通し

  • 主なハイライト
  • 市場規模分析と予測
  • 世界の尿路上皮がん診断市場の見通し：製品別
  • 世界の尿路上皮がん診断市場の見通し：検査別
  • 世界の尿路上皮がん診断市場の見通し：エンドユーザー別

第5章 世界の尿路上皮がん診断市場の見通し：地域別

  • 主なハイライト
  • 市場規模の歴史的分析、地域別、2019年～2024年
  • 現在の市場規模分析と予測、地域別、2025年～2032年
  • 市場の魅力分析：地域別

第6章 北米の尿路上皮がん診断市場の見通し

第7章 欧州の尿路上皮がん診断市場の見通し

第8章 東アジアの尿路上皮がん診断市場の見通し

第9章 南アジアおよびオセアニアの尿路上皮がん診断市場の見通し

第10章 ラテンアメリカの尿路上皮がん診断市場の見通し

第11章 中東・アフリカの尿路上皮がん診断市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Roche Holding
    • Illumina
    • IDL Biotech
    • Agilent Technologies
    • Olympus Corporation
    • Philips Healthcare
    • Abbott Molecular
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.（Qiagen NV）
    • Danaher Corporation（Cepheid）
    • GE Healthcare
    • Pacific Edge
    • Nonacus Limited
    • KDx Diagnostics Inc.
    • Sysmex Europe SE

第13章 付録

目次
Product Code: PMRREP14128

Persistence Market Research has recently released a comprehensive report on the worldwide market for urothelial carcinoma diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global urothelial carcinoma diagnostics market from 2025 to 2032.

Key Insights:

  • Urothelial Carcinoma Diagnostics Market Size (2025E): US$ 1,844.8 Mn
  • Projected Market Value (2032F): US$ 3,831.3 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 10.9%

Urothelial Carcinoma Diagnostics Market - Report Scope:

Urothelial carcinoma, commonly referred to as bladder cancer, is a prevalent malignancy requiring early and accurate diagnostics for effective treatment and patient outcomes. The market for urothelial carcinoma diagnostics includes a range of diagnostic modalities such as urine cytology, biomarker testing, fluorescence in situ hybridization (FISH), cystoscopy, and imaging techniques. These diagnostics play a crucial role in disease detection, staging, and monitoring recurrence. Market growth is driven by advancements in diagnostic technologies, increasing bladder cancer incidence, and the growing adoption of non-invasive diagnostic approaches, improving patient convenience and early detection rates.

Market Growth Drivers:

The global urothelial carcinoma diagnostics market is propelled by several key factors, including the rising prevalence of bladder cancer, particularly among aging populations and individuals with high-risk factors such as smoking and exposure to industrial chemicals. The growing preference for non-invasive and minimally invasive diagnostic methods, such as urine-based biomarker tests, is also contributing to market expansion. Additionally, technological advancements in molecular diagnostics and artificial intelligence-driven imaging solutions are enhancing diagnostic accuracy and efficiency. The increasing integration of liquid biopsy and next-generation sequencing (NGS) further supports market growth by offering precise, personalized diagnostic insights for urothelial carcinoma patients.

Market Restraints:

Despite promising growth prospects, the urothelial carcinoma diagnostics market faces challenges related to high diagnostic costs, limited accessibility in low-income regions, and reimbursement constraints. Many advanced diagnostic tests, including biomarker-based assays and genetic testing, remain expensive, limiting their widespread adoption in cost-sensitive markets. Furthermore, the complexity of regulatory approvals for novel diagnostic techniques poses barriers to market entry and innovation. Addressing these challenges requires collaboration among diagnostic manufacturers, healthcare providers, and policymakers to enhance affordability, accessibility, and regulatory harmonization.

Market Opportunities:

The urothelial carcinoma diagnostics market presents significant growth opportunities driven by the increasing adoption of artificial intelligence and machine learning in diagnostic imaging, the expansion of precision medicine approaches, and the rising focus on early cancer detection programs. Advancements in digital pathology and AI-assisted diagnostic platforms enhance diagnostic efficiency and reduce the likelihood of false positives or negatives, improving patient outcomes. Additionally, the development of cost-effective, rapid point-of-care diagnostic solutions for urothelial carcinoma could drive market penetration in underserved regions. Partnerships between diagnostic companies and research institutions to advance biomarker discovery and validation also offer lucrative growth prospects in this evolving market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urothelial carcinoma diagnostics market globally?
  • Which diagnostic modalities are witnessing the highest adoption in urothelial carcinoma detection and management?
  • How are technological advancements influencing the competitive landscape of the urothelial carcinoma diagnostics market?
  • Who are the key players contributing to the urothelial carcinoma diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global urothelial carcinoma diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urothelial carcinoma diagnostics market, including Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, and Bio-Rad Laboratories, focus on technological innovation, strategic collaborations, and product development to gain a competitive edge. These companies invest heavily in R&D to develop novel biomarker assays, liquid biopsy solutions, and AI-driven imaging tools for early and accurate detection of urothelial carcinoma. Partnerships with academic institutions and clinical research organizations facilitate the advancement of precision oncology diagnostics. Additionally, efforts to improve accessibility and affordability through pricing strategies, reimbursement advocacy, and expansion into emerging markets further support market growth.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Qiagen N.V.
  • Agilent Technologies
  • Illumina, Inc.
  • Siemens Healthineers
  • BD (Becton, Dickinson and Company)
  • Hologic, Inc.

Urothelial Carcinoma Diagnostics Market Segmentation

By Product

  • Reagent and Kits
  • Instruments

By Test

  • Urinalysis Test
  • Molecular Diagnostic Test
  • Biomarker Test

Cell-Based Test

  • Imaging Test
  • Cystoscopy
  • Ureteroscopy

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Clinical Research Organizations

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Urothelial Carcinoma Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Urothelial Carcinoma Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Urothelial Carcinoma Diagnostics Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Reagent and Kits
      • 4.3.3.2. Instruments
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Urothelial Carcinoma Diagnostics Market Outlook: Test
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Test, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
      • 4.4.3.1. Urinalysis Test
      • 4.4.3.2. Molecular Diagnostic Test
      • 4.4.3.3. Biomarker Test
        • 4.4.3.3.1. Immuno-Histochemical Assay Test
        • 4.4.3.3.2. In Situ Hybridization Test
        • 4.4.3.3.3. Biopsy
        • 4.4.3.3.4. Cell-Based Test
      • 4.4.3.4. Imaging Test
      • 4.4.3.5. Cystoscopy
      • 4.4.3.6. Ureteroscopy
    • 4.4.4. Market Attractiveness Analysis: Test
  • 4.5. Global Urothelial Carcinoma Diagnostics Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Diagnostic Laboratories
      • 4.5.3.3. Research and Academic Institutes
      • 4.5.3.4. Clinical Research Organizations
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Urothelial Carcinoma Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urothelial Carcinoma Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Test
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Reagent and Kits
    • 6.4.2. Instruments
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 6.5.1. Urinalysis Test
    • 6.5.2. Molecular Diagnostic Test
    • 6.5.3. Biomarker Test
      • 6.5.3.1. Immuno-Histochemical Assay Test
      • 6.5.3.2. In Situ Hybridization Test
      • 6.5.3.3. Biopsy
      • 6.5.3.4. Cell-Based Test
    • 6.5.4. Imaging Test
    • 6.5.5. Cystoscopy
    • 6.5.6. Ureteroscopy
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Diagnostic Laboratories
    • 6.6.3. Research and Academic Institutes
    • 6.6.4. Clinical Research Organizations
  • 6.7. Market Attractiveness Analysis

7. Europe Urothelial Carcinoma Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Test
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Reagent and Kits
    • 7.4.2. Instruments
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 7.5.1. Urinalysis Test
    • 7.5.2. Molecular Diagnostic Test
    • 7.5.3. Biomarker Test
      • 7.5.3.1. Immuno-Histochemical Assay Test
      • 7.5.3.2. In Situ Hybridization Test
      • 7.5.3.3. Biopsy
      • 7.5.3.4. Cell-Based Test
    • 7.5.4. Imaging Test
    • 7.5.5. Cystoscopy
    • 7.5.6. Ureteroscopy
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Diagnostic Laboratories
    • 7.6.3. Research and Academic Institutes
    • 7.6.4. Clinical Research Organizations
  • 7.7. Market Attractiveness Analysis

8. East Asia Urothelial Carcinoma Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Test
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Reagent and Kits
    • 8.4.2. Instruments
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 8.5.1. Urinalysis Test
    • 8.5.2. Molecular Diagnostic Test
    • 8.5.3. Biomarker Test
      • 8.5.3.1. Immuno-Histochemical Assay Test
      • 8.5.3.2. In Situ Hybridization Test
      • 8.5.3.3. Biopsy
      • 8.5.3.4. Cell-Based Test
    • 8.5.4. Imaging Test
    • 8.5.5. Cystoscopy
    • 8.5.6. Ureteroscopy
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Diagnostic Laboratories
    • 8.6.3. Research and Academic Institutes
    • 8.6.4. Clinical Research Organizations
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urothelial Carcinoma Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Test
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Reagent and Kits
    • 9.4.2. Instruments
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 9.5.1. Urinalysis Test
    • 9.5.2. Molecular Diagnostic Test
    • 9.5.3. Biomarker Test
      • 9.5.3.1. Immuno-Histochemical Assay Test
      • 9.5.3.2. In Situ Hybridization Test
      • 9.5.3.3. Biopsy
      • 9.5.3.4. Cell-Based Test
    • 9.5.4. Imaging Test
    • 9.5.5. Cystoscopy
    • 9.5.6. Ureteroscopy
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Diagnostic Laboratories
    • 9.6.3. Research and Academic Institutes
    • 9.6.4. Clinical Research Organizations
  • 9.7. Market Attractiveness Analysis

10. Latin America Urothelial Carcinoma Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Test
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Reagent and Kits
    • 10.4.2. Instruments
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 10.5.1. Urinalysis Test
    • 10.5.2. Molecular Diagnostic Test
    • 10.5.3. Biomarker Test
      • 10.5.3.1. Immuno-Histochemical Assay Test
      • 10.5.3.2. In Situ Hybridization Test
      • 10.5.3.3. Biopsy
      • 10.5.3.4. Cell-Based Test
    • 10.5.4. Imaging Test
    • 10.5.5. Cystoscopy
    • 10.5.6. Ureteroscopy
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Diagnostic Laboratories
    • 10.6.3. Research and Academic Institutes
    • 10.6.4. Clinical Research Organizations
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urothelial Carcinoma Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Test
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Reagent and Kits
    • 11.4.2. Instruments
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 11.5.1. Urinalysis Test
    • 11.5.2. Molecular Diagnostic Test
    • 11.5.3. Biomarker Test
      • 11.5.3.1. Immuno-Histochemical Assay Test
      • 11.5.3.2. In Situ Hybridization Test
      • 11.5.3.3. Biopsy
      • 11.5.3.4. Cell-Based Test
    • 11.5.4. Imaging Test
    • 11.5.5. Cystoscopy
    • 11.5.6. Ureteroscopy
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Diagnostic Laboratories
    • 11.6.3. Research and Academic Institutes
    • 11.6.4. Clinical Research Organizations
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Roche Holding
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Illumina
    • 12.3.3. IDL Biotech
    • 12.3.4. Agilent Technologies
    • 12.3.5. Olympus Corporation
    • 12.3.6. Philips Healthcare
    • 12.3.7. Abbott Molecular
    • 12.3.8. Bio-Rad Laboratories, Inc.
    • 12.3.9. Thermo Fisher Scientific, Inc. (Qiagen N.V.)
    • 12.3.10. Danaher Corporation (Cepheid)
    • 12.3.11. GE Healthcare
    • 12.3.12. Pacific Edge
    • 12.3.13. Nonacus Limited
    • 12.3.14. KDx Diagnostics Inc.
    • 12.3.15. Sysmex Europe SE

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations